Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
Portfolio Pulse from
Pharvaris presented long-term clinical data on deucrictibant for HAE at the 2025 AAAAI/WAO Joint Congress, showing safety and efficacy in Phase 3 studies.
March 03, 2025 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pharvaris presented positive long-term data for deucrictibant, a treatment for HAE, at a major medical congress. This could boost investor confidence as the drug progresses through Phase 3 trials.
The presentation of positive long-term safety and efficacy data for deucrictibant at a major congress is likely to enhance investor confidence in Pharvaris, as it indicates progress in their Phase 3 trials. This could lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100